Further, since γ-secretase is involved not only in Alzheimer's disease, but also in autoimmune diseases (including MS), where γ-secretase inhibitors are being tested for therapeutic benefit48, our findings draw attention to potential side effects of γ-secretase inhibitors related to the shedding of BCMA. This evidence concerns the gene TNFRSF17 and Alzheimer disease.